New Sugar-Tracking scan could reveal hidden inflammation

NCT ID NCT07253753

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new radioactive tracer called NeuCaVis in 12 healthy volunteers. Unlike standard PET scans that track glucose, NeuCaVis follows fructose, which is only used by inflamed tissues. The goal is to check safety and how the tracer spreads in the body, potentially leading to clearer images of disease in the brain and heart.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

12 people

The number who actually took part.

Started

Apr 2026

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female, ages 18-55 years inclusively at time of consent 2. Body Mass Index (BMI) of 18 to 30 kg/m2, inclusively 3. Capable of providing informed consent 4. Able to speak and read in English or French 5. Able to comply with all study procedures (including fasting for 12 hours, lying still in a supine position for about 90 minutes) Exclusion Criteria: 1. Known hypersensitivity NeuCaVis or its excipients 2. Blood glucose level higher than 200mg/dl at screening 3. Active viral infection at screening 4. Currently taking anti-inflammatory medications (e.g. ASA, NSAIDs, corticosteroids, immunomodulating agents, colchicine) 5. Any anatomical heart abnormality, or cardiovascular condition including acute cardiac condition, suspicion of cardiac inflammation, and/or coronary artery disease, that may confound the analysis of the data based on the investigator's clinical opinion. 6. Recent (in the past 6 months) history of head trauma 7. Abnormal and clinically significant results on the physical examination, vital signs, or laboratory tests at screening. 8. Clinically significant neurologic, neurodevelopmental, cardiovascular, renal, hepatic, hematological, gastrointestinal, pulmonary, or metabolic-endocrine disorder 9. Female participants who are pregnant, planning to become pregnant during the study or breastfeeding 10. If of childbearing potential, unwilling or unable to use of a highly effective method of contraception as outlined in the protocol for the duration of the study. 11. Any contraindication to PET or CT imaging. 12. Actively participating in other interventional clinical trial(s). 13. Unwilling to comply with study procedures, medication restrictions or attend all study visits 14. Any other condition that, in the opinion of the investigator, could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.